Syndax Pharmaceuticals, Inc. (SNDX) Net margin 2016–2025
Syndax Pharmaceuticals, Inc. (SNDX) net profit margin by fiscal year — reported net income divided by reported revenue.
-165.6%FY2025 · since FY2016: -3645.2% → -165.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -165.6% | +1180.5 pp |
| FY2024 | -1346.1% | — |
| FY2021 | 17.8% | +4840.4 pp |
| FY2020 | -4822.5% | -1127.9 pp |
| FY2019 | -3694.6% | +1180.9 pp |
| FY2018 | -4875.5% | -1991.1 pp |
| FY2017 | -2884.3% | +760.9 pp |
| FY2016 | -3645.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More SNDX financial trends
SNDX RevenueSNDX Net incomeSNDX Gross profitSNDX Gross marginSNDX Operating incomeSNDX Operating marginSNDX Operating cash flowSNDX Free cash flowSNDX Capital expendituresSNDX Return on equitySNDX Stock buybacksSNDX Dividends paidSNDX Total assetsSNDX Total liabilitiesSNDX Shareholders’ equitySNDX overview →